Role of Structured Education in Reducing Lypodistrophy and its Metabolic Complications in Insulin-Treated People with Type 2 Diabetes: A Randomized Multicenter Case-Control Study.

Sandro Gentile, Giuseppina Guarino, Teresa Della Corte, Giampiero Marino, Ersilia Satta, Maria Pasquarella, Carmine Romano, Carmelo Alfrone, Felice Strollo, AMD-OSDI Study Group on Injection Technique, Nefrocenter Research and Nyx Start-Up
Author Information
  1. Sandro Gentile: Department of Internal Medicine, Campania University "Luigi Vanvitelli", Naples, Italy. s.gentile1949@gmail.com. ORCID
  2. Giuseppina Guarino: Department of Internal Medicine, Campania University "Luigi Vanvitelli", Naples, Italy.
  3. Teresa Della Corte: Department of Internal Medicine, Campania University "Luigi Vanvitelli", Naples, Italy.
  4. Giampiero Marino: Department of Internal Medicine, Campania University "Luigi Vanvitelli", Naples, Italy.
  5. Ersilia Satta: Nefrocenter Research Network and Nyx Start-Up, Naples, Italy.
  6. Maria Pasquarella: Nefrocenter Research Network and Nyx Start-Up, Naples, Italy.
  7. Carmine Romano: Nefrocenter Research Network and Nyx Start-Up, Naples, Italy.
  8. Carmelo Alfrone: Nefrocenter Research Network and Nyx Start-Up, Naples, Italy.
  9. Felice Strollo: Endocrinology and Diabetes, IRCCS San Raffaele Pisana, Rome, Italy.

Abstract

INTRODUCTION: It is essential to use the correct injection technique (IT) to avoid skin complications such as lipohypertrophy (LH), local inflammation, bruising, and consequent repeated unexplained hypoglycemia episodes (hypos) as well as high HbA1c (glycated hemoglobin) levels, glycemic variability (GV), and insulin doses. Structured education plays a prominent role in injection technique improvement. The aim was to assess the ability of structured education to reduce (i) GV and hypos, (ii) HbA1c levels, (iii) insulin daily doses, and (iv) overall healthcare-related costs in outpatients with T2DM who were erroneously injecting insulin into LH.
METHODS: 318 patients aged 19-75 years who had been diagnosed with T2DM for at least 5 years, were being treated with insulin, were routinely followed by a private network of healthcare centers, and who had easily seen and palpable LH nodules were included in the study. At the beginning of the 6-month run-in period (T-6), all patients were trained to perform structured self-monitoring of blood glucose and to monitor symptomatic and severe hypos (SyHs and SeHs, respectively). After that (at T0), the patients were randomly and equally divided into an intervention group who received appropriate IT education (IG) and a control group (CG), and were followed up for six months (until T+6). Healthcare cost calculations (including resource utilization, loss of productivity, and more) were carried out based on the average NHS reimbursement price list.
RESULTS: Baseline characteristics were the same for both groups. During follow-up, the intra-LH injection rate for the CG progressively decreased to 59.9% (p < 0.001), a much smaller decrease than seen for the IG (1.9%, p < 0.001). Only the IG presented significant decreases in HbA1c (8.2 ± 1.2% vs. 6.2 ± 0.9%; p < 0.01), GV (247 ± 61 mg/dl vs. 142 ± 31 mg/dl; p < 0.01), insulin requirement (- 20.7%, p < 0.001), and SeH and SyH prevalence (which dropped dramatically from 16.4 to 0.6% and from 83.7 to 7.6%, respectively; p < 0.001). In the IG group only, costs-including those due to the reduced insulin requirement-decreased significantly, especially those relating to SeHs and SyHs, which dropped to €25.8 and €602.5, respectively (p < 0.001).
CONCLUSION: Within a 6-month observation period, intensive structured education yielded consistently improved metabolic results and led to sharp decreases in the hypo rate and the insulin requirement. These improvements resulted in a parallel drop in overall healthcare costs, representing a tremendous economic advantage for the NHS. These positive results should encourage institutions to resolve the apparently intractable problem of LH by financially incentivizing healthcare teams to provide patients with intensive structured education on proper injection technique.
TRIAL REGISTRATION: Trial registration no. 118/15.04.2018, approved by the Scientific and Ethics Committee of Campania University "Luigi Vanvitelli," Naples, Italy, and by the institutional review board (IRB Min. no. 9926 dated 05.05.2018).

Keywords

References

  1. Clin Diabetes. 2019 Jul;37(3):227-233 [PMID: 31371853]
  2. Mayo Clin Proc. 2016 Sep;91(9):1224-30 [PMID: 27594186]
  3. Curr Med Res Opin. 2010 Jun;26(6):1531-41 [PMID: 20429832]
  4. Nutr Metab Cardiovasc Dis. 2009 Jan;19(1):45-53 [PMID: 18450436]
  5. Springerplus. 2016 May 05;5:563 [PMID: 27213130]
  6. Acta Diabetol. 2011 Jun;48(2):121-5 [PMID: 20091324]
  7. Diabetes Technol Ther. 2002;4(5):673-82 [PMID: 12450450]
  8. Adv Ther. 2013 Oct;30(10):897-906 [PMID: 24170590]
  9. Diabetes Care. 2016 Sep;39(9):1486-92 [PMID: 27411698]
  10. Mayo Clin Proc. 2016 Sep;91(9):1212-23 [PMID: 27594185]
  11. JAMA. 2009 Apr 15;301(15):1565-72 [PMID: 19366776]
  12. Diabetes Care. 1988 Jan;11(1):41-5 [PMID: 3276476]
  13. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28 [PMID: 30559228]
  14. J Clin Transl Endocrinol. 2014 Jul 23;1(4):145-150 [PMID: 29159095]
  15. Mayo Clin Proc. 2016 Sep;91(9):1231-55 [PMID: 27594187]
  16. Diabet Med. 1990 May;7(4):335-42 [PMID: 2140087]
  17. Horm Metab Res. 1983 Jun;15(6):274-8 [PMID: 6409773]
  18. Diabetes Care. 2013 Apr;36(4):894-900 [PMID: 23223349]
  19. Br Med J (Clin Res Ed). 1986 Jun 21;292(6536):1638 [PMID: 3087555]
  20. Diabetes Res Clin Pract. 2017 Apr;126:248-253 [PMID: 28288434]
  21. BMJ. 1990 Jul 7;301(6742):3-4 [PMID: 2200543]
  22. BMJ. 2013 Jul 29;347:f4533 [PMID: 23900314]
  23. J Diabetes Metab Disord. 2017 Nov 14;16:45 [PMID: 29164077]
  24. Diabetes Res Clin Pract. 2018 Sep;143:320-321 [PMID: 30076872]
  25. Diabetes. 2008 Dec;57(12):3169-76 [PMID: 19033403]
  26. Diabetes Ther. 2019 Aug;10(4):1423-1433 [PMID: 31222593]
  27. Nutr Metab Cardiovasc Dis. 2017 Mar;27(3):209-216 [PMID: 28017523]
  28. Diabetes Technol Ther. 2017 Nov;19(11):623-632 [PMID: 29058477]
  29. Diabetes Metab. 2013 Oct;39(5):445-53 [PMID: 23886784]
  30. Diabetes Ther. 2021 Jan;12(1):107-119 [PMID: 33219928]
  31. Diabetes Metab Syndr. 2019 Jan - Feb;13(1):682-686 [PMID: 30641790]
  32. JAMA Intern Med. 2013 Jul 22;173(14):1300-6 [PMID: 23753199]
  33. Diabet Med. 1990 Aug;7(7):600-2 [PMID: 2146067]
  34. Curr Med Res Opin. 2010 Jun;26(6):1519-30 [PMID: 20429833]
  35. Diabetes Ther. 2020 Sep;11(9):2001-2017 [PMID: 32683659]
  36. J Diabetes Investig. 2017 Sep 01;: [PMID: 28862814]
  37. Diabetes Care. 1990 Jan;13(1):74-6 [PMID: 2404719]

Word Cloud

Created with Highcharts 10.0.0insulinp < 0education001injectionLHstructuredpatientsIGtechniquehyposHbA1cGVcostshealthcarerespectivelygroup9%ITlevelsvariabilitydosesStructuredoverallT2DMfollowedseen6-monthperiodSyHsSeHsCGNHSratedecreases8vs01requirementdropped6%7intensiveresults201805EducationINTRODUCTION:essentialusecorrectavoidskincomplicationslipohypertrophylocalinflammationbruisingconsequentrepeatedunexplainedhypoglycemiaepisodeswellhighglycatedhemoglobinglycemicplaysprominentroleimprovementaimassessabilityreduceiiiiidailyivhealthcare-relatedoutpatientserroneouslyinjectingMETHODS:318aged19-75 yearsdiagnosedleast5 yearstreatedroutinelyprivatenetworkcenterseasilypalpablenodulesincludedstudybeginningrun-inT-6trainedperformself-monitoringbloodglucosemonitorsymptomaticsevereT0randomlyequallydividedinterventionreceivedappropriatecontrolsixmonthsT+6HealthcarecostcalculationsincludingresourceutilizationlossproductivitycarriedbasedaveragereimbursementpricelistRESULTS:Baselinecharacteristicsgroupsfollow-upintra-LHprogressivelydecreased59muchsmallerdecrease1presentedsignificant2 ± 12%62 ± 0247 ± 61 mg/dl142 ± 31 mg/dl- 207%SeHSyHprevalencedramatically164083costs-includingduereducedrequirement-decreasedsignificantlyespeciallyrelating€25€6025CONCLUSION:WithinobservationyieldedconsistentlyimprovedmetabolicledsharphypoimprovementsresultedparalleldroprepresentingtremendouseconomicadvantagepositiveencourageinstitutionsresolveapparentlyintractableproblemfinanciallyincentivizingteamsprovideproperTRIALREGISTRATION:Trialregistration118/1504approvedScientificEthicsCommitteeCampaniaUniversity"LuigiVanvitelli"NaplesItalyinstitutionalreviewboardIRBMin9926datedRoleReducingLypodistrophyMetabolicComplicationsInsulin-TreatedPeopleType2Diabetes:RandomizedMulticenterCase-ControlStudyDiabetesDirectindirectGlycemicHypoglycemiaLipohypertrophy

Similar Articles

Cited By (8)